We computed the probability that each statin agent was the best treatment in terms of inducing less DM.
The ranking of the competing drugs was assessed with the median of the posterior distribution for the rank of each drug; cumulative
ranking probabilities curves for competing statin treatments were built. The surface under the cumulative ranking curve
(SUCRA) was derived by using the posterior probabilities for each treatment to be among the n best options;